

Special Issue

Cancer Epigenetic Biomarkers

Message from the Guest Editor

Cancer represents one of the most threatening human diseases, with millions of diagnosed novel cases and deaths occurring worldwide every year. The global aging of the population and the increased exposure to environmental carcinogens, coupled with the adoption of lifestyle behaviors such as smoking, poor diets, and scarce physical activity, account for the majority of cancers in both developed and less-developed countries. It is also well ascertained that genetic, epigenetic, and cytogenetic modifications occur within cancer cells and tissue, many of which are driven by environmental exposures and are responsible for the acquisition of the malignant phenotype. Particularly, it is now clear that hundreds of genes change their expression in the multistep process of carcinogenesis as a consequence of epigenetic events, including promoter hypermethylation, histone-tail modifications, chromatin remodeling, or interference mechanisms mediated by non-coding RNA molecules. This Special Issue will focus on the most recent advances in cancer epigenetics, as well as on the discovery and utility of cancer epigenetic biomarkers.

Guest Editor

Prof. Dr. Fabio Coppedè

Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa, 56126 Pisa, Italy

Deadline for manuscript submissions

closed (20 May 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/95112

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)